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Stem cells: the new “model organism”
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ABSTRACT Human tissue culture cells have long been a staple of molecular and cell biology 
research. However, although these cells are derived from humans, they have often lost con-
siderable aspects of natural physiological function. Here we argue that combined advances in 
genome editing, stem cell production, and organoid derivation from stem cells represent a 
revolution in cell biology. These advances have important ramifications for the study of basic 
cell biology mechanisms, as well as for the ways in which discoveries in mechanisms are trans-
lated into understanding of disease.
Tissue culture cells have long proven to be convenient vehicles for 
studies in molecular and cell biology and continue to yield funda-
mental discoveries in mechanism. However, the widespread use of 
most common tissue culture cell lines for such studies is problematic 
for several reasons. First, these lines have considerable aneuploidy, 
chromosome translocations, and genome instability. Such chromo-
somal abnormalities are expected, as they are hallmarks of the 
tumors from which most cell lines were derived. Chromosomal 
aberrations are a problem because they result in abnormal gene 
expression. Chromosome instability is a problem because cellular 
phenotypes are unstable. Exacerbating the chromosomal instability 
problem is the fact that common cell lines have been passaged ex-
tensively, and so, as an example, HeLa cells in one lab may bear very 
little resemblance to HeLa cells in another lab (Hyman and Simons, 
2011). These sources of phenotypic perturbation and variation cre-
ate nonphysiological conditions that change unpredictably over 
time. Detecting effects of experimental perturbations in a geneti-
cally unstable cellular background can be very difficult, and the non-
physiological state of the cells throws doubt on the biological rele-
vance of the observations. Moreover, effects of the cancer mutations 
in these tumor-derived lines on cell structure and physiology cloud 
the ability to draw conclusions about mechanisms that function in 
the normal cell state.
Mechanistic studies of cellular processes in a natural physiological 
setting have been greatly enhanced by the availability of “model” 
organisms, which are selected in part because their genomes contain 
a normal, stable complement of genes and chromosomes (Rine, 
2014). Moreover, these organisms are traceable to a common ances-
tral parent, with care being taken to minimize the number of genera-
tions separating each individual studied from the original parent. 
These model organisms include such lab staples as Escherichia coli 
bacteria, budding and fission yeast, nematodes, maize, the mouse-
ear cress Arabidopsis thaliana, fruit flies, and mice. Because essen-
tially all laboratory budding yeast strains can be traced to one of two 
parent lines, S288c and W303, variation caused by genetic differ-
ences is minimized, and both natural and experimentally introduced 
variation can be readily detected (Hall and Linder, 1993). In Cae-
norhabditis elegans research, the widespread use of the N2 line, for 
which the original isolate is still available, has been a crucial aspect of 
the success of this model organism (Brenner 1974).
Here we argue that stem cells, which include embryonic stem 
cells (ES), induced pluripotent stem cells (iPS), and adult stems cells 
(see Box 1), combine many of the advantages of tissue culture mod-
els with those of the traditionally employed model organisms. The 
following list includes what we see as the major advantages of using 
stem cells for the study of problems in molecular and cell biology.
1. Stem cells represent a normal physiological state because they 
are typically derived from healthy tissues.
2. Their genomes lack the abnormalities that characterize most tis-
sue culture lines (Figure 1). Recent work has shown that the 
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Box 1. Definitions of stem cell types.
Adult stem cells (also called somatic stem cells): Stem cells found 
throughout the adult body to maintain the body’s tissues.
iPS cells: Induced pluripotent stem cells. Stem cells derived from 
differentiated cells in adult tissues.
ES cells: Embryonic stem cells. Stem cells derived from embryos.
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4. Organoids can be produced from stem 
cells. Because they represent many tissue 
types, organoids allow cellular processes 
to be studied in the context of a differen-
tiated tissue (Figure 2; e.g., Lancaster 
and Knoblich, 2014; Clevers, 2016; 
Fatehullah et al., 2016). Moreover, tissues 
made from stem cells can also be used 
for drug screening. For example, organ-
oids made from gut adult stem cells 
are already used in the clinic in certain 
situations (van de Wetering et al., 2015). 
Organoid production is still in its infancy. 
For example, organoids are often miss-
ing key aspects of normal tissue physiol-
ogy, such as vascularization. However, 
improvement in organoids is essentially a 
problem in engineering, and we can be 
confident that as greater resources are 
poured into their production, especially 
in the commercial world, they will, over 
the next decades, approach the physio-
logical state of organs formed during 
normal development.
5. Genome editing first used zinc finger 
nucleases, then transcription activator–
like effector nucleases (TALENS), and 
now clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9. It is now routine to integrate fluorescent pro-
tein coding sequences (e.g., green fluorescent protein and red 
fluorescent protein) in-frame at the chromosomal locus of any 
protein-coding gene so the fluorescent protein fusion is ex-
pressed from the native promoter of the gene of interest with-
out ectopic overexpression (Doyon et al., 2011) and to con-
struct mutants at any genomic locus. Genetically encoded tags 
inserted at the genomic locus avoid fixation artifacts and over-
expression artifacts (Doyon et al., 2011; Gibson et al., 2013) 
and make possible real-time analysis of protein dynamics in 
live cells. Introduction of these tags at the endogenous locus 
by genome editing also makes it possible to count molecules 
within macromolecular structures in living cells. One only 
needs to calibrate the fluorescence produced from known 
numbers of reference fluorescent proteins (Dambournet et al., 
2014; Grassart et al., 2014). Genome editing can of course be 
applied to all tissue culture systems. Because stem cells can be 
differentiated into many cell types and tissues, however, ge-
nome editing also allows essentially any mutation engineered 
in any gene in the stem cells to be expressed in different cell 
types and organoids derived from the parent stem cell line car-
rying the engineered mutant. This powerful approach provides 
a sensitive isogenic system for detecting effects of the muta-
tions and determining how they affect different cell types and 
tissues.
6. As cell biologists, we have often had an uneasy relationship 
with translational research. Many of our studies are in model 
organisms, and considerable time is needed before discover-
ies in these models can be translated to address human dis-
ease. Working in stems cells allows cell biologists to investi-
gate fundamental mechanisms, secure in the knowledge that 
their discoveries can be rapidly translated into understanding 
disease.
genomes of adult stem cells passaged in culture are remarkably 
stable (Martins-Taylor and Xu, 2012), although it is always advis-
able to minimize passages.
3. Stem cells can be differentiated into many different cell types 
whose phenotypic differences can be reliably detected and stud-
ied in isogenic cells that were all derived from a common parent 
cell line (Noggle et al., 2005).
FIGURE 2: Cross-section of a human brain organoid grown for 42 d. 
Forebrain cells (progenitors and neurons) are labeled in green and a 
subpopulation of forebrain progenitors in red. All nuclei are labeled in 
blue. Image provided by Veronica Krenn and Juergen Knoblich.
FIGURE 1: Karyotypes of WTC iPS cells (A) and HeLa cells (B, C). Note that the WTC cells have a 
normal chromosomal complement, whereas the HeLa cells are characterized by many irregularities 
in chromosome number (B) and by massive translocations revealed by a spectral karyotype 
(C). Reproduced with permission from Mandegar et al., 2016 (A) and Macville et al., 1999 (B, C).
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In conclusion, the past half-century has witnessed a remarkable 
increase in understanding of basic cellular mechanisms. The intro-
duction of stem cells, which can be differentiated into multiple dif-
ferent cell types and tissues, will herald similar advances in our 
understanding of how basic cellular mechanisms are modulated 
during the healthy process of differentiation and the pathological 
consequences of disease.
Considering these advantages, it seems clear that cell biology is 
entering a new era in which mechanistic studies can be conducted in 
systems that are close in physiology to human biology and that cell 
biologists should enthusiastically embrace this shift in emphasis. 
Most cell biologists are unfamiliar with the techniques and procedures 
necessary to work with stem cells. Therefore the community must 
make resources and training available for such an endeavor. Such 
resources will be particularly important for stem cells in part because 
of the current costs involved and partly because of the care needed 
to maintain the stem cell state while modifying their genome. As 
stem cells become more widely adopted, costs should be expected 
to decline and more robust protocols to manipulate and maintain the 
cells developed.
A particularly promising development in this direction is the efforts 
of the Allen Institute for Cell Science to use genome editing in stem 
cells to construct a collection of isogenic cell lines endogenously ex-
pressing fluorescent protein fusions. The idea for the focus of this ef-
fort came in part from discussions among the leadership of the Ameri-
can Society for Cell Biology on how to make such modified stem cells 
as widely available as possible (www.ascb.org/files/ASCB-Position 
-Paper-Stem-Cell-Report.pdf; www.ascb.org/newsletter/november 
december-2016).
The Allen Institute is engineering, into one parental stem cell 
line, in-frame gene fusions whose hybrid protein products will mark 
most major cellular structures and signaling pathways. The geneti-
cally encoded fluorescent tags are being inserted at the natural 
chromosomal locus for each gene to minimize perturbation of ex-
pression. Each of these gene fusions is being constructed in the 
same well-characterized, parental iPS cell line, WTC, which was cre-
ated in the Conklin lab at the University of California, San Francisco, 
and is a true pluripotent diploid with a stable genome (Kreitzer 
et al., 2013). Of importance, there are no licensing restrictions on 
distribution of the parent WTC line, which it turns out is somewhat 
unusual. The genome-engineered stem cell lines constructed at the 
Allen Institute will be available to all researchers, promising to pro-
vide for studies of human cells in culture many of the advantages of 
the commonly used model organisms. Of importance, although it is 
routine in model organisms to backcross an engineered locus to the 
wild-type parent several times to ensure that no other changes 
picked up during editing are being carried in the genome, this is not 
possible with engineered stem cells. To address this deficiency, the 
Allen Institute is implementing rigorous quality controls and keep-
ing multiple independent clones (Roberts et al., 2017).
If these genome-engineered cell lines and the protocols for 
culturing and differentiating them are widely adopted, as is an-
ticipated, progress in many studies of molecular and cell biology 
and the translation of the results to address human health issues 
will be substantially enhanced. In addition, comparisons of re-
sults obtained in different labs using these isogenic diploid, plu-
ripotent sibling cell lines will be considerably more meaningful 
than comparisons between results from studies on different tis-
sue culture lines.
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